Loading...
XSHE000952
Market cap263mUSD
Dec 26, Last price  
5.59CNY
1D
0.90%
1Q
2.38%
Jan 2017
-64.91%
Name

Hubei Guangji Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:000952 chart
P/E
—
P/S
2.61
EPS
—
Div Yield, %
1.64%
Shrs. gr., 5y
3.32%
Rev. gr., 5y
-2.65%
Revenues
738m
-7.50%
276,625,120345,834,010388,696,038794,903,350571,782,750448,197,426483,316,187453,316,737394,156,326487,080,365485,858,038560,355,471714,723,953801,556,325843,830,942731,340,517688,169,323837,106,649797,642,746737,819,479
Net income
-140m
L
8,213,3818,563,82915,664,893183,801,72589,097,44543,003,75313,979,6024,845,51002,421,979020,921,468141,839,233105,211,595171,728,90986,943,19474,647,103110,107,17350,333,654-140,248,068
CFO
-149m
L
054,138,642125,954,626331,975,678220,700,152077,177,84081,878,424108,020,36495,158,31400167,074,831178,828,210231,438,796144,200,478119,381,52575,907,30345,079,614-148,963,590
Dividend
May 27, 20220.06 CNY/sh
Earnings
May 29, 2025

Profile

Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, medicinal feed additives, fine chemicals, and preparations in China. The company also exports its products to approximately 30 countries and regions worldwide. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.
URL
https://www.guangjipharm.com/
IPO date
Nov 12, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
737,819
-7.50%
797,643
-4.71%
837,107
21.64%
Cost of revenue
819,463
649,503
663,780
Unusual Expense (Income)
NOPBT
(81,644)
148,140
173,327
NOPBT Margin
18.57%
20.71%
Operating Taxes
11,748
12,366
18,532
Tax Rate
8.35%
10.69%
NOPAT
(93,391)
135,774
154,795
Net income
(140,248)
-378.64%
50,334
-54.29%
110,107
47.50%
Dividends
(31,562)
(21,159)
(20,640)
Dividend yield
1.11%
0.78%
0.77%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
291,063
357,243
336,727
Long-term debt
421,784
251,336
37,747
Deferred revenue
15,654
18,121
21,045
Other long-term liabilities
335,318
56,950
329
Net debt
262,403
133,094
41,349
Cash flow
Cash from operating activities
(148,964)
45,080
75,907
CAPEX
Cash from investing activities
(565,781)
Cash from financing activities
701,086
300,942
FCF
(379,929)
(59,516)
26,249
Balance
Cash
415,244
431,353
293,332
Long term investments
35,201
44,131
39,794
Excess cash
413,553
435,603
291,271
Stockholders' equity
885,547
1,157,081
1,143,135
Invested Capital
2,040,469
1,719,017
1,540,163
ROIC
8.33%
10.74%
ROCE
6.88%
9.46%
EV
Common stock shares outstanding
355,779
352,705
343,977
Price
7.99
4.31%
7.66
-1.35%
7.76
5.65%
Market cap
2,842,674
5.22%
2,701,719
1.16%
2,670,867
8.67%
EV
3,134,080
2,834,812
2,712,216
EBITDA
38,306
246,451
264,585
EV/EBITDA
81.82
11.50
10.25
Interest
49,151
21,101
16,684
Interest/NOPBT
14.24%
9.63%